In this multicenter real‐world analysis, we demonstrated that temporal muscle thickness at baseline and over time serves as a robust prognostic biomarker in newly diagnosed MGMT promoter methylated glioblastoma patients treated with radiochemotherapy. The gene discussed is MGMT; the disease is glioblastoma.